Loading patent…
AssigneeBioNTech RNA Pharmaceuticals GmbH
InventorsDirk Schadendorf, Annette Paschen, Silke Lübcke, Martina Fatho, Daniela Eberts, Hakim Echchannaoui, Volker Lennerz, Catherine Woelfel, Thomas Woelfel
Estimating the term…
The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention. The invention further pertains to pharmaceutical compositions, especially vaccine compositions, comprising the antigens, nucleic acids, binding agents or T cells in accordance with the invention, and methods for the generation of T cells, which are specifically reactive to the antigens of the invention in an MHC-independent manner.
A binding agent that is a T cell receptor, comprising (i) a) T cell receptor alpha chain, or a binding fragment thereof, comprising SEQ ID NO 9, 10 and 11;
An isolated T cell, comprising a T-cell receptor (TCR) that binds to a protein, protein fragment or polypeptide comprising at least 8 contiguous amino acids from the amino add sequence of GM-CSF-Receptor alpha chain (CSF2RA) (SEQ ID NO:
Dependencies are inferred from the claim text.